Novo Nordisk, Danish pharmaceutical company, reports impressive profits amidst increasing competition in the industry.
In a recent report, Danish pharmaceutical giant Novo Nordisk revealed a 18% increase in sales for the second quarter, totalling 76 billion Danish kroner ($12.2 billion). However, this growth was not evenly distributed across all markets. The company is experiencing a significant slowdown in sales of its diabetes and obesity treatments Ozempic and Wegovy in the United States.
The U.S. market is facing increased competition, with compounded (copycat) drugs and rival pharmaceutical companies like Eli Lilly posing a significant threat. These unapproved versions of Wegovy and Ozempic, which contain the same active ingredient (semaglutide), provide cheaper alternatives for U.S. patients. Despite the Food and Drug Administration's warnings against such compounding due to safety concerns, these drugs continue to penetrate the market, eroding Novo Nordisk’s market share and sales growth.
Novo Nordisk's competing product Zepbound, from Eli Lilly, is directly challenging Wegovy’s position, adding to the sales pressures domestically. As a result, Novo Nordisk has had to revise its 2025 sales growth forecast for Wegovy to 8-14% from an earlier 13-21%, and lower its expected operating profit growth to 10-16% from 16-24%. This revision was due to “persistent use of compounded drugs, slower than expected market expansion, and competition,” especially in the U.S.
In response, Novo Nordisk has taken legal and strategic measures. The company has filed over 130 lawsuits across 40 states to combat illegal compounded semaglutide drugs and is pursuing broader legal actions to protect its market. Additionally, Novo Nordisk has deepened direct-to-consumer efforts and secured insurance formulary preferences to improve access and market share.
These competitive challenges have had a significant impact on Novo Nordisk's share price, leading to a nearly 50% share value loss earlier in 2025. The company has also undergone a CEO transition, cost-cutting initiatives, and investor lawsuits alleging that Novo underestimated the impact of compounded drug competition on sales.
Despite these challenges, Novo Nordisk's global sales for diabetes and obesity drugs, including Ozempic and Wegovy, grew overall in early 2025 but at a slowing pace. The U.S. remains the most affected region by competition and compounded drug penetration.
The second quarter, as reported by Novo Nordisk, saw a 32% increase in net profit, totalling 26.5 billion Danish kroner ($4.1 billion). Readers can find more related articles on topics such as the financial outlook of Danish companies, the state of the shipping industry, housing affordability in Denmark, and the average Danish lifestyle.
We invite our readers to join the conversation in the comments section below. Your views, questions, or suggestions are always welcome. Please note that the comments section is subject to our terms of use.
[1] "Gross disappointment": Danish pharma giant Novo Nordisk cuts earning forecasts. (2025). Retrieved from our website
[2] Danish shipping giant Maersk raises outlook with non-US demand high. (2025). Retrieved from our website
[3] MAP: What income do you need to buy a home in Denmark in 2025? (2025). Retrieved from our website
[4] Food, sport and love: How does the average Dane really live? (2025). Retrieved from our website
[5] Legal and strategic responses: Novo Nordisk files over 130 lawsuits to combat illegal compounded semaglutide drugs. (2025). Retrieved from our website
- The increased competition in the U.S. market, particularly from Eli Lilly's competing product Zepbound and unapproved versions of Ozempic and Wegovy, has led to a significant slowdown in sales for Novo Nordisk's diabetes and obesity treatments, impacting the overall art of business and financial-conditions for the company.
- The challenging market for Novo Nordisk's diabetes and obesity drugs, such as Ozempic and Wegovy, has resulted in a lowering of the company's 2025 sales growth forecast, affecting its health-and-wellness sector and consequently, its investment strategies and share price.
- In response to the competition and compounded drug penetration, primarily in the U.S., Novo Nordisk has taken legal actions and implemented direct-to-consumer strategies, which also influences the broader medical-conditions and business landscape.
